SynthesisCancer research communications2026
Identifying and Addressing Barriers to Live Primary Prostate Cancer Cell Research in Veterans.
Synthesis in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Increased comorbidities and unique service-related exposures among veterans may contribute to unique tumor biology that can influence tumor behavior and response to treatment. Research that incorporates live cells from veteran donors can support investigation of the genomic and transcriptomic biology of veteran tumors as well as how those molecular alterations affect tumor function, such as growth, metastasis, and treatment sensitivity. We conducted a systematic literature review to assess veteran-focused prostate cancer studies published in the last decade that incorporate live primary cells. We found that in the past 10 years, 105 prostate cancer studies were published that utilized live primary cells from the general population compared with zero studies utilizing live primary cells from veterans. Analysis of veterans enrolled in a study utilizing live primary cells at the William S Middleton Veterans Affairs demonstrated that 94% of veterans who were presented with a live cell biospecimen donation study ultimately enrolled. Furthermore, survey responses from veterans enrolled in this study showed that 83% of veterans found their research engagement to be a meaningful experience and 70% reported increased healthcare satisfaction as a result of their participation. These findings suggest that the lack of live cell prostate cancer research in veterans seems to be due to a lack of research opportunities for veterans and not a lack of veteran interest in participation Finally, we demonstrate that implementation of an informatics-based patient screening strategy can potentially support more veteran-focused studies by reducing participant screening time by 89%. SIGNIFICANCE: Live primary cells are a unique model for prostate cancer research that provides both molecular and functional readouts to support advances in veteran prostate cancer care. We detail the shortage of live primary research in veterans and address potential barriers to future studies incorporating this model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.